Back to search

Article

10-Year Analysis of the Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Disease

2025-08-13

Abstract excerpt

<h4>Background: </h4> Patients with chronic obstructive pulmonary disease (COPD) and coronary heart disease (CHD) are at increased risk for community-acquired pneumonia (CAP), contributing to higher morbidity and mortality. Pneumococcal vaccination may offer protective benefits in this population. This study aimed to evaluate the effects of the 13-valent pneumococcal conjugate vaccine (PCV13) on reducing CAP cases...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1248482f-5777-516a-8730-26780881cbbc
DOI
10.20944/preprints202508.0886.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
10-Year Analysis of the Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart DiseaseDOI 10.20944/preprints202508.0886.v1
Impact of 13-valent pneumococal conjugate polysaccharide vaccination in exacerbations rate of COPD patients with moderate to severe obstruction.Semantic proximity
Dynamics of the pneumococcal population causing acute exacerbations in COPD patients in a Barcelona hospital (2009-12): comparison with 2001-04 and 2005-08 periods.Semantic proximity
Waning of SARS-Cov-2 vaccine effectiveness against delta variant in COPD patientsSemantic proximity
Effects of pneumococcal vaccine in patients with chronic respiratory diseaseSemantic proximity
Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccinesSemantic proximity
Outburst of serotype 4 IPD after COVID-19 is driven by ST15063/GPSC162 lineage associated with high-risk behaviors and greater virulence linked to influenza H3N2 virus coinfection and cigarette smokeSemantic proximity
Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies.Semantic proximity
Pneumococcal Diseases Caused by Serotype Replacement in Colombia: A Cost-Effectiveness Analysis of Pneumococcal Conjugate Vaccines in Infants and Its Herd Protection in Older AdultsSemantic proximity
Cost-Effectiveness Analysis of Pneumococcal Vaccine in the Pediatric Population: A Systematic ReviewSemantic proximity
Intranasal Immunization With an Attenuated pep27 Mutant Provides Protection From Influenza Virus and Secondary Pneumococcal Infections.Semantic proximity
Pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: a retrospective record linkage cohort studySemantic proximity
Differences in Pneumococcal Serotype Replacement in Individuals with and without Underlying Medical ConditionsSemantic proximity
Select a neighboring publication to make it the new centre.